You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

self amplifying RNA vaccine

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

COVID-19 Vaccines Trial in Ho Chi Minh City, Ha Noi (ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine, Placebo (normal saline),

Active, not recruiting
  • COVID-19 Vaccines
  • ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
  • +2 more
  • Ho Chi Minh City, Ho Chi Minh, Vietnam
  • +2 more
Mar 14, 2022

Influenza, Human Trial in Brisbane (ARCT-2138, Licensed Quadrivalent Vaccine for younger adults, Licensed Quadrivalent Vaccine

Not yet recruiting
  • Influenza, Human
  • ARCT-2138
  • +2 more
  • Brisbane, Queensland, Australia
    Nucleus Network Brisbane Clinic
Nov 8, 2023

Influenza, Human Trial in United States (PF-07852352 Influenza saRNA 1, PF-07836391 Influenza saRNA, PF-07836394 Influenza

Recruiting
  • Influenza, Human
  • PF-07852352 Influenza saRNA 1
  • +10 more
  • Phoenix, Arizona
  • +23 more
Jan 17, 2023

Influenza, Human Trial (sa-mRNA vaccine Dose 1, sa-mRNA vaccine Dose 2, sa-mRNA vaccine Dose 3)

Not yet recruiting
  • Influenza, Human
  • sa-mRNA vaccine Dose 1
  • +4 more
  • (no location specified)
Sep 7, 2023

COVID-19 Trial in Entebbe (LNP-nCOV saRNA-02 Vaccine)

Recruiting
  • COVID-19
  • LNP-nCOV saRNA-02 Vaccine
  • Entebbe, Uganda
    MRC/UVRI & LSHTM Uganda Research Unit
Apr 14, 2022

COVID-19, COVID-19 Vaccine Trial (RNA MCTI CIMATEC HDT 5µg, RNA MCTI CIMATEC HDT 10µg, Covishield® - AstraZeneca)

Not yet recruiting
  • COVID-19
  • COVID-19 Vaccine
  • RNA MCTI CIMATEC HDT 5µg
  • +3 more
  • (no location specified)
Sep 13, 2022

SARS-CoV-2 Trial in Salvador (Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine, Cohort 2 RNA VACCINE MCTI CIMATEC

Recruiting
  • SARS-CoV-2
  • Cohort 1 VACCINE RNA MCTI CIMATEC HDT (HDT-301) vaccine
  • +3 more
  • Salvador, Bahia, Brazil
    Hospital da Bahia
Mar 23, 2022

COVID-19 Trial in Birmingham, Leicester, Manchester (GRT-R910 10 mcg Dose (after AZ), GRT-R910 30 mcg Dose (after AZ), GRT-R910

Recruiting
  • COVID-19
  • GRT-R910 10 mcg Dose (after AZ)
  • +3 more
  • Birmingham, United Kingdom
  • +2 more
Aug 15, 2022

SARS-CoV2 Infection Trial in Renton (HDT-301)

Active, not recruiting
  • SARS-CoV2 Infection
  • HDT-301
  • Renton, Washington
    Rainier Clinical Research
Jan 16, 2023

COVID-19, SARS-CoV-2 Trial in Johannesburg, Pretoria (GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9,

Recruiting
  • COVID-19
  • SARS-CoV-2
  • GRT-R912, samRNA-Spikebeta-TCE11
  • +2 more
  • Johannesburg, South Africa
  • +1 more
Jun 24, 2022

COVID-19, SARS-CoV-2 Infection, Corona Virus Infection Trial in Wichita, Kansas City, Singapore (ARCT-165, ARCT-154, ARCT-021)

Recruiting
  • COVID-19
  • +2 more
  • ARCT-165
  • +2 more
  • Wichita, Kansas
  • +2 more
Nov 10, 2021

Covid19, SARS-CoV Infection, Corona Virus Infection Trial in Singapore, United States (ARCT-021 single dose priming, ARCT-021

Terminated
  • Covid19
  • +2 more
  • ARCT-021 single dose priming
  • +5 more
  • Chandler, Arizona
  • +14 more
Jul 7, 2022

Colonic Tumors, Colorectal Tumors Trial in Detroit, New York, Cincinnati (GRT-C901, GRT-R902, Atezolizumab)

Recruiting
  • Colonic Neoplasms
  • Colorectal Neoplasms
  • Detroit, Michigan
  • +2 more
Aug 1, 2022

COVID-19 Trial in Johannesburg (AAHI-SC2 Vaccine, AAHI-SC3 Vaccine, EUA or approved vaccine)

Recruiting
  • COVID-19
  • AAHI-SC2 Vaccine
  • +2 more
  • Johannesburg, South Africa
    Wits Vida
Jan 4, 2023

SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2 (Omi XBB.1.5))

Not yet recruiting
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b2 (Omi XBB.1.5)
  • Dublin, California
  • +14 more
Aug 10, 2023

Shingles, Herpes Zoster Infection, Human Trial (Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection,

Not yet recruiting
  • Shingles
  • +2 more
  • Candidate 1: PF-07915234: VZV modRNA Powder for Suspension for Injection
  • +6 more
  • (no location specified)
Jan 19, 2023

COVID-19 Trial (Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose, Bivalent BNT162b2 (original/Omicron BA.4/BA.5)

Not yet recruiting
  • COVID-19
  • Bivalent BNT162b2 (original/Omicron BA.4/BA.5) 3 microgram dose
  • +3 more
  • (no location specified)
Dec 22, 2022

Herpes Zoster (HZ), Shingles, Infectious Disease Trial in Hollywood, Tampa, Berlin (JCXH-105, Active Control (Shingrix))

Recruiting
  • Herpes Zoster (HZ)
  • +2 more
  • JCXH-105
  • Active Control (Shingrix)
  • Hollywood, Florida
  • +2 more
May 23, 2023

SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b5 Bivalent (WT/OMI BA.2), BNT162b2 Bivalent (WT/OMI BA.1))

Recruiting
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b5 Bivalent (WT/OMI BA.2)
  • BNT162b2 Bivalent (WT/OMI BA.1)
  • Anaheim, California
  • +9 more
Aug 8, 2022

Influenza, Human, COVID-19 Trial in United States (bivalent BNT162b2 (original/Omi BA.4/BA.5), qIRV (22/23), QIV)

Recruiting
  • Influenza, Human
  • COVID-19
  • bivalent BNT162b2 (original/Omi BA.4/BA.5)
  • +2 more
  • Athens, Alabama
  • +18 more
Dec 22, 2022

Virus Diseases Trial in Rochester (1 µg CoV2 SAM (LNP))

Completed
  • Virus Diseases
  • 1 µg CoV2 SAM (LNP)
  • Rochester, New York
    GSK Investigational Site
May 16, 2022

SARS-CoV-2 Infection, COVID-19 Trial in United States (BNT162b2, BNT162b2.B.1.351)

Completed
  • SARS-CoV-2 Infection
  • COVID-19
  • BNT162b2
  • BNT162b2.B.1.351
  • Oakland, California
  • +16 more
Feb 17, 2022

Pulmonary Osteosarcoma Trial (RNA-LP vaccine)

Not yet recruiting
  • Pulmonary Osteosarcoma
  • RNA-LP vaccine
  • (no location specified)
Jan 25, 2023

COVID-19, SARS-CoV-2 Trial in Seoul (QTP104 1ug, QTP104 5ug, QTP104 25ug)

Active, not recruiting
  • COVID-19
  • SARS-CoV-2
  • QTP104 1ug
  • +2 more
  • Seoul, Korea, Republic of
  • +1 more
May 24, 2023

Malaria Trial (BNT165e, Placebo)

Not yet recruiting
  • Malaria
  • BNT165e
  • Placebo
  • (no location specified)
Sep 29, 2023